Drilldown: Medicines

Rimegepant (1) · Rizatriptan (benzoate) (1) · Sumatriptan (succinate) (1)

Imitrex (oral, injectable, nasal), Tosymra (nasal spray), Onzetra Xsail (nasal powder), Zembrace SymTouch (low-dose autoinjector), Sumavel DosePro (needle-free SC) (1) · Maxalt (tablet), Maxalt-MLT (orally disintegrating tablet) (1) · Nurtec ODT (1)

Research material · Classic Psychedelic · Stimulant · Opioid · Sedative-Hypnotic · Phenethylamine · Tryptamine · Benzodiazepine · Botanical · [[:Category:Antihypertensives|Antihypertensive]] · Dissociative · Anticonvulsant · Antidepressant · Plant Medicine · Analgesic · Antipsychotic · Antiparkinsonian · Empathogen · Neuroleptic · Cathinone

Other values:

Search

None (3)

'"`UNIQ--vote-00000011-QINU`"' (1) · '"`UNIQ--vote-00000013-QINU`"', '"`UNIQ--vote-00000014-QINU`"' (2)

5-10 mg PO at migraine onset; may repeat after 2 hours, maximum 30 mg/24 hours (1) · Acute migraine: 75 mg PO at onset, maximum one dose per 24 hours. Preventive: 75 mg PO every other day (1) · Oral: 50-100 mg at migraine onset, may repeat in 2 hours if needed. SC: 6 mg, may repeat in 1 hour. Nasal: 5-20 mg per nostril, may repeat in 2 hours (1)

Oral tablets 25, 50, 100 mg; SC injection 4, 6 mg autoinjector; needle-free SC 6 mg (Sumavel); nasal spray 5, 20 mg; nasal powder 22 mg (Onzetra Xsail); low-dose autoinjector 3 mg (Zembrace SymTouch) (1) · Orally disintegrating tablet 75 mg (1) · Tablets 5, 10 mg; ODT (Maxalt-MLT) 5, 10 mg (1)

200 mg/day (oral); 12 mg/day (SC); 40 mg/day (nasal spray); 44 mg/day (Onzetra) (1) · 30 mg/24 hours (1) · 75 mg per dose; one dose per 24 hours (acute); one dose every other day (preventive) (1)

intranasal (1) · Oral (2) · Oral (sublingual disintegration) (1) · subcutaneous (1)

1-2 hours for migraine relief (1) · 10 minutes (SC); 15-30 minutes (nasal); 30-60 minutes (oral) (1) · 30 minutes for migraine relief (1)

2-4 hours; headache recurrence rate ~20-30% within 24 hours (1) · 4-6 hours; headache recurrence is common (1) · ~48 hours of headache freedom (1)

2 hours'"`UNIQ--ref-00000015-QINU`"' (1) · 2-3 hours'"`UNIQ--ref-00000012-QINU`"' (1) · ~11 hours'"`UNIQ--ref-00000015-QINU`"' (1)

~14% (oral; substantial first-pass); ~97% (subcutaneous); ~17% (nasal)'"`UNIQ--ref-00000016-QINU`"' (1) · ~45% (oral; substantially higher than sumatriptan's ~14%)'"`UNIQ--ref-00000013-QINU`"' (1) · ~64% (oral)'"`UNIQ--ref-00000016-QINU`"' (1)

Limited human data.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Limited human data; pregnancy registry data have been broadly reassuring across the triptan class.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Limited human data; pregnancy registry data have been broadly reassuring relative to baseline malformation rates.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)

[[USLegal:Prescription only|Rx-only]] in US (3)